When the treatment is the culprit: Prevalence of allergens in prescription topical steroids and immunomodulators - 19/06/20
Doi : 10.1016/j.jaad.2019.11.020
Jennifer M. Tran, BA, Margo J. Reeder, MD ⁎ 
Department of Dermatology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin
∗Correspondence to: Margo J. Reeder, MD, Department of Dermatology, University of Wisconsin School of Medicine and Public Health, 1 S Park St, 7th floor, Madison, WI 53715Department of DermatologyUniversity of Wisconsin School of Medicine and Public Health1 S Park St, 7th floorMadisonWI53715
| Funding sources: None. |
|
| Conflicts of interest: None disclosed. |
|
| Reprints not available from the authors. |
© 2019
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 83 - N° 1
P. 228-230 - juillet 2020 Retour au numéro
Article précédent
- Modeling of usage and estimation of cost for efinaconazole 10% topical solution in the treatment of onychomycosis
- Krysta Lin, Shari R. Lipner
- Treatments and associated outcomes of acral lentiginous melanoma: A review
- Marissa B. Lobl, Chelsea Santos, Dillon Clarey, Shauna Higgins, Edibaldo Silva-Lopez, Adam Sutton, Ashley Wysong
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?